Patents by Inventor Sascha Bossow
Sascha Bossow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210252085Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: ApplicationFiled: February 3, 2021Publication date: August 19, 2021Inventors: Christine Engeland, Guy Ungerechts, Sascha Bossow
-
Patent number: 11028409Abstract: A genome-replication-deficient and transcription/competent negative/strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development. In particular, a recombinant Sendia virus containing a viral genome with a mutation in the gene P, which leads to loss of capacity for replication without loss of capacity for secondary transcription, and at least one sequence coding for a heterologous gene product. Furthermore, a nucleocapsid of the Sendai virus, a genome of the Sendai virus, a DNA molecule that codes for the genome and/or antigenome of the Sendai virus. One aspect is a pharmaceutical composition containing the Sendai virus, the nucleocapsid, or the viral genome as active substance, and a medical use thereof, especially as a vaccine.Type: GrantFiled: May 25, 2017Date of Patent: June 8, 2021Assignee: MAX-PLANCK-GESELLSCHAFT ZUR FĂ–RDERUNG DER WISSENSCHAFTEN E.V.Inventors: Wolfgang J. Neubert, Sascha Bossow, Sabine Schlecht
-
Patent number: 10933106Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: GrantFiled: February 24, 2015Date of Patent: March 2, 2021Assignee: DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Christine Engeland, Guy Ungerechts, Sascha Bossow
-
Publication number: 20190099461Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: ApplicationFiled: December 13, 2018Publication date: April 4, 2019Applicants: Deutsches Krebsforschungszentrum, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGInventors: Guy UNGERECHTS, Tobias SPECK, Christine ENGELAND, Sascha BOSSOW
-
Patent number: 10172894Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: GrantFiled: August 25, 2016Date of Patent: January 8, 2019Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM, RUPRECHT-KARLS-UNIVERSITAET HEIDELBERGInventors: Guy Ungerechts, Tobias Speck, Christine Engeland, Sascha Bossow
-
Publication number: 20180142256Abstract: The present invention relates to a genome-replication-deficient and transcription-competent negative-strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development.Type: ApplicationFiled: May 25, 2017Publication date: May 24, 2018Inventors: Wolfgang J. Neubert, Sascha Bossow, Sabine Schlecht
-
Patent number: 9821016Abstract: The present invention relates to a genetically modified Paramyxovirus, a pharmaceutical composition comprising this paramyxovirus, the use of a genetically modified Paramyxovirus for the therapeutic and/or prophylactic treatment of a tumor disease, and a method for the production of a pharmaceutical composition for the therapeutic or prophylactic treatment of a tumor disease.Type: GrantFiled: October 22, 2012Date of Patent: November 21, 2017Assignee: Eberhard-Karls-Universitaet Tuebingen UniversitaetsklinikumInventors: Ulrich Manfred Lauer, Michael Bitzer, Martina Zimmermann, Sorin Armeanu-Ebinger, Sascha Bossow, Wolfgang Neubert
-
Patent number: 9795643Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.Type: GrantFiled: May 22, 2015Date of Patent: October 24, 2017Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Schell, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
-
Publication number: 20170128505Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a multispecific binding polypeptide, said multispecific binding polypeptide comprising a first binding domain binding to a surface molecule of an immune cell with antitumor activity, preferably a lymphocyte, more preferably a T cell or a dendritic cell, and a second binding domain binding to a tumor-associated antigen; to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: ApplicationFiled: August 25, 2016Publication date: May 11, 2017Inventors: Guy UNGERECHTS, Tobias SPECK, Christine ENGELAND, Sascha BOSSOW
-
Publication number: 20170065650Abstract: The present invention relates to a recombinant virus of the family Paramyxoviridae, comprising at least one expressible polynucleotide encoding a secreted activator of the immune response, to a polynucleotide encoding the same, and to a kit comprising the same. Moreover, the present invention relates to a method for treating cancer in a subject afflicted with cancer, comprising contacting said subject with a recombinant virus of the family Paramyxoviridae of the invention, and thereby, treating cancer in a subject afflicted with cancer.Type: ApplicationFiled: February 25, 2015Publication date: March 9, 2017Inventors: Christine Engeland, Guy Ungerechts, Sascha Bossow
-
Patent number: 9272008Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.Type: GrantFiled: August 19, 2011Date of Patent: March 1, 2016Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Zimmermann, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
-
Publication number: 20150250838Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.Type: ApplicationFiled: May 22, 2015Publication date: September 10, 2015Inventors: Ulrich M. LAUER, Michael BITZER, Johanna LAMPE, Martina ZIMMERMANN, Susanne BERCHTOLD, Sebastian LANGE, Wolfgang J. NEUBERT, Sascha BOSSOW
-
Publication number: 20130217757Abstract: The present invention pertains to a pharmaceutical composition comprising a recombinant measles virus encoding a suicide gene for use in the treatment of malignant cells with primary or secondary resistances against an oncolytic measles virus without suicide gene activity. Further, the present invention pertains to a recombinant measles virus based on measles vaccine strain Schwarz encoding a suicide gene, which comprises a fusion of a cytosine deaminase, particularly yeast cytosine deaminase, and a uracil phosphoribosyltransferase, particularly yeast uracil phosphoribosyltransferase, to a method and a kit for preparing the recombinant measles virus as claimed herein.Type: ApplicationFiled: August 19, 2011Publication date: August 22, 2013Inventors: Ulrich M. Lauer, Michael Bitzer, Johanna Lampe, Martina Zimmermann, Susanne Berchtold, Sebastian Lange, Wolfgang J. Neubert, Sascha Bossow
-
Publication number: 20110142811Abstract: The present invention concerns recombinant measles virus as a therapeutic, in particular a recombinant measles virus comprising a suicide gene in its genome, a mutated viral hemagglutinin, and a specificity domain specifically recognizing a cancer antigen. Furthermore, it relates to a polynucleotide coding for such a recombinant measles virus and a vector comprising said polynucleotide. The current invention also relates to a method for the manufacture of and a medicament comprising said recombinant measles virus, as well as a method for treating a solid tumor using said recombinant measles virus.Type: ApplicationFiled: December 16, 2009Publication date: June 16, 2011Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUMInventors: Guy UNGERECHTS, Christof Von Kalle, Sascha Bossow
-
Publication number: 20090041725Abstract: The present invention relates to a genome-replication-deficient and transcription-competent negative-strand RNA virus, which can be used for the expression of transgenes and in particular for the area of vaccine development.Type: ApplicationFiled: August 9, 2007Publication date: February 12, 2009Inventors: Wolfgang J. Neubert, Sascha Bossow, Sabine Schlecht